skip to main content

HT29-5M21

HT29-5M21

Catalogue No.

15121706

Cell Line Name

HT29-5M21

Cell Line Description

HT-29-5M21 is a mucus-secreting clone of HT29 which forms a monolayer of polarized cells with strong anti-gastric mucin immunoreactivity and mainly expresses MUC5AC and MUC5B. It is resistant to MTX and sensitive to 5-FU.

Characteristics

Receptors

Apical brush border, dipeptidylpeptidase IV, carcinoembryonic antigen, and villin

Products

Cells at confluence form a monolayer of polarised cells with string anti-gastric immunoreactivity MUC5AC and MUC5B.

Tissue of Origin

Colon

Morphology

Epithelial

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11,12
D3S1358: 15
D5S818: 11,12
D7S820: 10
D8S1179: 10
D13S317: 11
D16S539: 11,12
D18S51: 13
D21S11: 29
FGA: 20,22
Penta D: 11
Penta E: 14,16
TH01: 6,9
TPOX: 8,9
vWA: 17

Applications

Defining the biological characteristics of tumour cells resistant to current therapeutics to promote the development of new treatment strategies

Disease

Adenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding can be as low as 0.32 x10⁴ cells/cm² up to 4 x10⁴ cells/cm², using 0.05% trypsin/EDTA solution. Cells are cultured at 37°C, in 90% air and 10% CO₂, and passaged every 3 to 4 days.

Culture Medium

DMEM containing 10% FBS, 2mM L-Glutamine and 10 µM Methotrexate

Growth Mode

Adherent

Additional Info

Depositor

CelluloNet

Country of Origin

France

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, Huet G, Lesuffleur T. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell. 2004 Mar;96 (2):145-51. PMID: 15050369.

Bibliography

Lesuffleur T, Violette S, Vasile-Pandrea I, Dussaulx E, Barbat A, Muleris M, Zweibaum A. Resistance to high concentrations of methotrexate and 5-fluorouracil of differentiated HT-29 colon-cancer cells is restricted to cells of enterocytic phenotype. Int J Cancer. 1998 May 4;76 (3):383-92. PMID: 9579576 Dessein AF, Stechly L, Jonckheere N, Dumont P, Monté D, Leteurtre E, Truant S, Pruvot FR, Figeac M, Hebbar M, Lecellier CH, Lesuffleur T, Dessein R, Grard G, Dejonghe MJ, de Launoit Y, Furuichi Y, Prévost G, Porchet N, Gespach C, Huet G. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res. 2010 Jun 1;70(11):4644-54. PMID: 20460542.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: HT29-5M21 (ECACC 15121706).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.